U.S. License Holder:
Amgen / Allergan
Date of License:
KANJINTI (trastuzumab-anns) is a HER2/neu receptor antagonist indicated for:
The treatment of HER2-overexpressing breast cancer;
The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Kanjinti (Amgen / Allergan) (May-2018)
Biosimilars Approved In Australia
Kanjinti (Amgen) (May-2019)
U.S. Patent LitigationsPACER
U.S. Patent Nos.
6,121,428 (Protein Recovery) 6,242,177 (Methods and Compositions for Secretion of Heterologous Polypeptides) 6,331,415 (Methods of Producing Immunoglobulins, Vectors and Transformed Host Cells for Use Therein) 6,407,213 (Method for Making Humanized Antibodies) 6,417,335 (Protein Purification) 6,489,447 (Protein Purification) 6,586,206 (Methods for Making Recombinant Proteins Using Apoptosis Inhibitors 6,620,918 (Separation of Polypeptide Monomers) 6,627,196 (Dosages for Treatment with Anti-ErbB2 Antibodies) 6,870,034 (Protein Purification) 7,371,379 (Dosages for Treatment with Anti-ErbB2 Antibodies) 7,449,184 (Fixed Dosing of HER Antibodies) 7,501,122 (Treatment with Anti-ErbB2 Antibody Combinations) 7,846,441 (Treatment with Anti-ERBB2 Antibodies) 7,892,549 (Treatment with anti-ErbB2 antibodies) 7,923,221 (Methods of Making Antibody Heavy and Light Chains having Specificity for a Desired Antigen) 7,993,834 (Detection of ErbB2 Gene Amplification to Increase the Likelihood of the Effectiveness of ErbB2 Antibody Breast Cancer Therapy) 8,044,017 (Protein Purification) 8,076,066 (Gene Detection Assay for Improving the Likelihood of an Effective Response to a HER2 Antibody Cancer Therapy) 8,314,225 (Heavy Chain Mutant Leading to Improved Immunoglobulin Production) 8,357,301 (Chromatography Equipment Characterization) 8,425,908 (Treatment with Anti-ErbB2 Antibodies) 8,440,402 (Gene Detection Assay for Improving the Likelihood of an Effective Response to a HER2 Antibody Cancer Therapy) 8,460,895 (Method for Producing Recombinant Proteins with a Constant Content of pCO2 in the Medium) 8,512,983 (Production of Proteins in Glutamine-Free Cell Culture Media) 8,574,869 (Prevention of Disulfide Bond Reduction During Recombinant Production of Polypeptides) 8,691,232 (Extending Time to Disease Progression or Survival in Cancer Patients) 8,710,196 (Protein Purification) 8,771,988 (Protein Expression from Multiple Nucleic Acids) 9,047,438 (Chromatography Equipment Characterization) 9,080,183 (Promoter) 9,249,218 (Protein Purification) 9,428,766 (Protein Expression from Multiple Nucleic Acids) 9,487,809 (Decreasing Lactate Level and Increasing Polypeptide Production by Downregulating the Expression of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase) 9,493,744 (Methods for Viral Inactivation and Other Adventitious Agents) 9,714,293 (Production of Proteins in Glutamine-free Cell Culture Media) 9,868,760 (Protein Purification) 10,160,811 (Treatment with Anti-ErbB2 Antibodies)
City of Hope; Genentech, Inc.
Federal Circuit Appeal(s)
19-2156 (TRO and PI)
Case Ongoing; Federal Circuit Affirmed Denial of of Temporary Restraining Order and Preliminary Injunction